Data sharing provides a huge potential for translational medicine by fostering secondary research, innovation, transparency and reproducibility. Privacy concerns in this context can be addressed by privacy-enhancing technologies (PETs) such as anonymization. Anonymization alters data in a way that it can no longer be related to a person which, in turn, might lead to reduced data quality (privacy-utility trade-off). However, evidence of utility-preserving anonymization is accumulating. Utility most often refers to general-purpose utility metrics. In our study, in contrast, we focused on utility in a real-world application (the German Chronic Kidney Disease study) and checked for replicability of research results while scaling privacy.